CN114072206B - 治疗方法 - Google Patents

治疗方法 Download PDF

Info

Publication number
CN114072206B
CN114072206B CN202080046367.0A CN202080046367A CN114072206B CN 114072206 B CN114072206 B CN 114072206B CN 202080046367 A CN202080046367 A CN 202080046367A CN 114072206 B CN114072206 B CN 114072206B
Authority
CN
China
Prior art keywords
seq
nomacopan
ala
protein
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080046367.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN114072206A (zh
Inventor
维恩·H·维斯顿-戴维斯
V·卡尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volution Immuno Pharmaceuticals SA
Original Assignee
Volution Immuno Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals SA filed Critical Volution Immuno Pharmaceuticals SA
Publication of CN114072206A publication Critical patent/CN114072206A/zh
Application granted granted Critical
Publication of CN114072206B publication Critical patent/CN114072206B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080046367.0A 2019-04-25 2020-03-04 治疗方法 Active CN114072206B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1905810.6 2019-04-25
GBGB1905810.6A GB201905810D0 (en) 2019-04-25 2019-04-25 Method of treatment
GB2000955.1 2020-01-22
GBGB2000955.1A GB202000955D0 (en) 2019-04-25 2020-01-22 Method of treatment
PCT/EP2020/055741 WO2020216513A1 (en) 2019-04-25 2020-03-04 Method of treatment

Publications (2)

Publication Number Publication Date
CN114072206A CN114072206A (zh) 2022-02-18
CN114072206B true CN114072206B (zh) 2024-11-08

Family

ID=66810336

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080046367.0A Active CN114072206B (zh) 2019-04-25 2020-03-04 治疗方法

Country Status (10)

Country Link
US (1) US20220211810A1 (https=)
EP (1) EP3958974A1 (https=)
JP (1) JP7603612B2 (https=)
KR (1) KR20220018963A (https=)
CN (1) CN114072206B (https=)
AU (1) AU2020263709A1 (https=)
CA (1) CA3137240A1 (https=)
GB (2) GB201905810D0 (https=)
IL (1) IL287250A (https=)
WO (1) WO2020216513A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
WO2024238859A1 (en) * 2023-05-16 2024-11-21 Regenxbio Inc. Vectorized c5 inhibitor agents and administration thereof
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018193120A1 (en) * 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of cicatrising eye inflammatory disorders
WO2018193121A1 (en) * 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin variants lacking c5 binding

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1629098B1 (en) 2003-06-02 2009-04-01 Varleigh Limited Complement inhibitors from ticks
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
PL2061501T3 (pl) 2006-09-08 2016-01-29 Volution Immuno Pharmaceuticals Sa Sposób leczenia zaburzeń oddechowych
AU2008228247A1 (en) * 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
SI2173890T1 (sl) * 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) * 2009-04-20 2009-06-03 Natural Environment Res Council Composition
JP5840623B2 (ja) 2010-01-08 2016-01-06 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 気道のウイルス感染症の治療に用いるｅｖ５７６
GB201401453D0 (en) * 2014-01-28 2014-03-12 Univ Birmingham Transmucosal and transepithelial drug delivery system
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
CA2988313A1 (en) 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
EP3359566A1 (en) * 2015-10-07 2018-08-15 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
SG11201811491YA (en) * 2016-06-27 2019-01-30 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders
AU2018226872A1 (en) * 2017-03-03 2019-09-05 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
US11730792B2 (en) * 2017-04-21 2023-08-22 Volution Immuno Pharmaceuticals Sa Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA)
JP7629394B2 (ja) * 2018-09-10 2025-02-13 ヴォリューション イミュノ ファーマシューティカルズ エスエイ リウマチ性疾患の治療に使用するためのコバーシン
US20220370556A1 (en) * 2019-09-27 2022-11-24 Volution Immuno Pharmaceuticals Sa Method of Treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018193120A1 (en) * 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of cicatrising eye inflammatory disorders
WO2018193121A1 (en) * 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin variants lacking c5 binding

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Drusen complement components C3a and C5a promote choroidal neovascularization;Miho Nozaki等;PNAS;20060214;第103卷(第7期);2328-2333 *

Also Published As

Publication number Publication date
JP2022530068A (ja) 2022-06-27
GB202000955D0 (en) 2020-03-04
EP3958974A1 (en) 2022-03-02
US20220211810A1 (en) 2022-07-07
CN114072206A (zh) 2022-02-18
CA3137240A1 (en) 2020-10-29
AU2020263709A1 (en) 2021-12-23
JP7603612B2 (ja) 2024-12-20
GB201905810D0 (en) 2019-06-05
WO2020216513A1 (en) 2020-10-29
IL287250A (en) 2021-12-01
KR20220018963A (ko) 2022-02-15

Similar Documents

Publication Publication Date Title
CN110896606B (zh) 用于治疗自身免疫性水疱病的coversin
CN114072206B (zh) 治疗方法
US9260506B2 (en) Treatment of retinal disorders with recombinant T cell receptor ligand (RTL)
CA2666843C (en) Treatment of age-related macular degeneration and other diseases of the eye
KR20190138650A (ko) 반흔성 안구 염증성 장애의 치료를 위한 코버신
TW202227131A (zh) 帕金森氏症之治療
AU2019468121A1 (en) Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
WO2005118799A1 (en) Ovine hyaluronidase
WO2013005603A1 (ja) 結膜におけるアレルギー性炎症の予防及び／又は治療剤
JP2022542889A (ja) ドライアイ疾患のためのｔｓｇ６ポリペプチドフラグメント
AU2012385960A1 (en) Method of treating hyperglycemic disorders using apolipoprotein AIV
KR20090115801A (ko) 맥락막 신생혈관용 백신 치료
WO2024115767A1 (en) Nomacopan-pas fusion proteins
WO2018088464A1 (ja) 脳梗塞の治療薬
Heinke Michalska-Małecka

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant